As biosimilars become increasingly available, they are creating a competitive market with originator products, but uptake of biosimilars among patients is varied and depends on factors like patient demographics, geography, site of care, prescriber specialty, and insurance type, according to two recent studies published in the journal Health Affairs.
Molly Beinfeld, of Tufts University, told Regulatory Focus in an interview that she and her colleagues are “somewhat optimistic” about the biosimilar market…
